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Abstract 17 
Transient receptor potential melastatin 2 (TRPM2), is a ligand-gated Ca2+-permeable non-18 
selective cation channel. While physiological stimuli, e.g. chemotactic agents, evoke 19 
controlled Ca2+ signals via TRPM2, pathophysiological signals, such as reactive oxygen 20 
species or genotoxic stress result in prolonged TRPM2-mediated Ca2+ entry and consequently 21 
apoptosis. To date, adenosine 5ʹ-diphosphoribose (ADPR, 1) has been assumed to be the main 22 
agonist for TRPM2. Here, we show that 2ʹ-deoxy-ADPR 2 was a significantly better TRPM2 23 
 2 
 
 
agonist, inducing 10.4-fold higher whole cell currents at saturation. Mechanistically, this 24 
increased activity was caused by decreased rate of inactivation and higher average open 25 
probability. Using high performance liquid chromatography (HPLC) and mass spectrometry, 26 
endogenous 2ʹ-deoxy-ADPR was detected in Jurkat T-lymphocytes. Consistently, cytosolic 27 
nicotinamide mononucleotide adenylyltransferase 2 (NMNAT-2) and nicotinamide adenine 28 
dinucleotide (NAD)-glycohydrolase CD38 sequentially catalyzed synthesis of 2ʹ-deoxy-29 
ADPR from nicotinamide mononucleotide and 2ʹ-deoxy-ATP in vitro. Thus, 2ʹ-deoxy-ADPR 30 
is an endogenous TRPM2 superagonist that may act as cell signaling molecule. 31 
 32 
Introduction 33 
The C-terminal domain of TRPM2 is homologous to ADPR pyrophosphatase NUDT9. This 34 
discovery resulted in the identification of adenosine 5ʹ-diphosphoribose (ADPR, 1) as its 35 
agonist1. An increase in cellular ADPR to activate TRPM2 is thought to proceed by 36 
hydrolysis of β-NAD either by NAD-glycohydrolase CD38 or via concerted action of poly-37 
ADPR polymerases (PARPs) and poly-ADPR glycohydrolase (PARG) (reviewed in 2). The 38 
half maximal effective concentration (EC50) for activation of TRPM2 by ADPR (reviewed in 39 
3) implies that a significant amount of cellular NAD must be converted to ADPR to achieve 40 
activation. While this may make sense for the induction of apoptosis or cell death4,5, it appears 41 
rather unlikely to be the case for physiological activation of TRPM2, e.g. in chemotaxis6, 42 
insulin secretion7, or thermosensation8,9. Alternative activation mechanisms have been 43 
described, including direct activation by hydrogen peroxide10, by intracellular Ca2+ ions11 or 44 
by O-acetyl-ADPR12. 45 
In summary, we show that among various ADPR analogues only 2ʹ-deoxy-ADPR 2, 3ʹ-deoxy-46 
ADPR 17, 2ʹ-phospho-ADPR 15, and 2-F-ADPR 13 activated TRPM2. 2ʹ-Deoxy-ADPR 2 47 
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activated TRPM2 with similar potency but higher efficacy than ADPR, making 2ʹ-deoxy-48 
ADPR a TRPM2 superagonist. The massive increase in macroscopic current induced by 2ʹ-49 
deoxy-ADPR was due to decelerated TRPM2 inactivation and a higher average open 50 
probability, while the single channel conductance remained unaffected. Further, we 51 
demonstrate formation of 2ʹ-deoxy-ADPR in vitro in two steps: from NMN and 2ʹ-deoxy-52 
ATP to 2ʹ-deoxy-NAD as catalyzed by NMNAT-2, and from 2ʹ-deoxy-NAD to 2ʹ-deoxy-53 
ADPR catalyzed by CD38. Finally, we proved the presence of endogenous 2ʹ-deoxy-ADPR 54 
and 2ʹ-deoxy-NAD and present evidence for hydrogen peroxide-evoked increase of 2ʹ-deoxy-55 
ADPR in Jurkat T cells. Importantly, 2ʹ-deoxy-ADPR is not only a significantly better agonist 56 
regarding TRPM2 activation than ADPR, but in addition does not require any NAD 57 
consumption for its synthesis. 2ʹ-deoxy-ADPR thus exhibits many of the properties expected 58 
of a second messenger.  59 
 60 
Results 61 
2ʹ-Deoxy-ADPR as a TRPM2 superagonist 62 
Our interest in 2ʹ-deoxy-ADPR as a potential TRPM2 agonist began when we probed the 63 
structural requirements for activation of the channel. We assessed the agonist activity of 64 
ADPR  analogues (Supplementary Results, Supplementary Fig. 1–4) we had previously 65 
evaluated as potential TRPM2 inhibitors13. These analogues feature modifications in the 66 
purine base, the adenosine ribose, the pyrophosphate group and the terminal ribose. Published 67 
EC50 values for the activation of TRPM2 by ADPR are in the micromolar range (between 68 
1 µmol/L and 90 µmol/L)3 indicating an interaction of rather low affinity. We therefore 69 
anticipated that many of the analogues might activate TRPM2. To our surprise most of the 70 
analogues had no, or negligible, agonist activity (Fig. 1). Among the ADPR analogues with 71 
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modifications at the purine ring only 2-F-ADPR retained partial agonist activity (Fig. 1). 72 
These results clearly demonstrate the requirement of a combination of terminal ribose, 73 
pyrophosphate, and adenosine motifs for activation of TRPM2. 74 
The part of ADPR most permissive to modifications was the adenosine ribose (Fig. 2). 2ʹ-75 
Phospho-ADPR showed partial agonist activity albeit at higher concentrations (EC50 76 
110 µmol/L) and with reduced efficacy (0.56 nA ± 0.64 nA, best-fit value ± standard error 77 
(SE)) compared to ADPR (1.60 nA ± 0.47 nA, best-fit value ± SE) (Fig. 2a), in good 78 
agreement with a recent study14. The most interesting finding, however, came from our 79 
attempt to establish the role of the 2ʹ- and 3ʹ-hydroxyl groups of the adenosine ribose. While 80 
3ʹ-deoxy-ADPR showed an EC50 comparable to that of ADPR (EC50 46 µmol/L and 81 
28 µmol/L, respectively) and elicited only a slightly reduced maximum current (1.23 nA ± 82 
0.52 nA, best-fit value ± SE), 2ʹ-deoxy-ADPR activated TRPM2 at somewhat lower 83 
concentrations than ADPR (Fig. 2a). Most importantly, 2ʹ-deoxy-ADPR induced 10.4-fold 84 
higher currents in the whole cell configuration (Fig. 2a). Whole cell patch clamp experiments 85 
with the human T cell line Jurkat that endogenously expresses TRPM24,15–17 confirmed the 86 
induction of significantly higher currents by 2ʹ-deoxy-ADPR as compared to ADPR. In 87 
contrast to HEK293 cells, Jurkat cells in the majority of experiments did not tolerate 2ʹ-88 
deoxy-ADPR concentrations > 100 µmol/L, likely due to the high Ca2+ and Na+ influx (Fig. 89 
2b). Under physiological ionic conditions, in these experiments the I-V curve obtained from 90 
voltage ramps was nearly linear and was characterized by a reversal potential near 0 91 
(Supplementary Fig. 5b), regardless of the activating agonist. These results clearly 92 
demonstrate that 2ʹ-deoxy-ADPR is a TRPM2 superagonist.  93 
The increase in whole cell current after activation by superagonists might be explained either 94 
by the preferential occupation of higher conductance states, as has been shown for the 95 
insecticide clothianidin, a superagonist of the nicotinic acetylcholine receptor18, by induction 96 
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of an otherwise inaccessible higher conductance state, or by a change in kinetics allowing the 97 
channel to remain in the open state for longer periods of time, as is the case for 4,5,6,7-98 
tetrahydroisoxazolo[5,4-c]pyridin-3(2H)-one (THIP), a superagonist of the α4β3δ GABA 99 
receptor19. To distinguish between these possibilities we performed recordings on excised 100 
inside/out patches from cells expressing either wild type hTRPM2 (Fig 3a+b+c) or hTRPM2 101 
with modified selectivity filter (T5L) that shows increased affinity to permeating cations 102 
resulting in higher single channel conductivity20. The results showed no significant difference 103 
in single channel conductance (Fig. 3c) upon activation by either ADPR or 2ʹ-deoxy-ADPR. 104 
Instead, the inactivation of TRPM2 following 2ʹ-deoxy-ADPR activation was significantly 105 
slower compared to ADPR (Fig 3d+e+f; 2ʹ-deoxy ADPR: 0.050 s-1 ± 0.003 s-1 vs ADPR: 106 
0.037 s-1 ± 0.003 s-1, best-fit values ± SE, extra sum-of-squares F test, p=0.001). Further, the 107 
average open probability was 37% higher (Fig. 3d+g) for activation by 2ʹ-deoxy-ADPR  108 
(median 0.92, interquartile range (IQR) 0.80 to 0.97) compared to ADPR (median 0.67, IQR 109 
0.17 to 0.74, Mann-Whitney test, p< 0.0001). In addition, we also observed an approx. 5-fold 110 
increase in the number of channels simultaneously in the open state when excised patches 111 
were exposed to 2ʹ-deoxy-ADPR (Fig. 3d+h), at least partially attributable to the increased 112 
open probability. Whole cell patch clamp experiments with different Ca2+ concentrations in 113 
the pipette buffer solution demonstrated a reduced Ca2+-sensitivity of activation of TRPM2 by 114 
2ʹ-deoxy-ADPR when compared to activation by ADPR (Fig. 2c). Whereas the maximum 115 
current induced by ADPR (as obtained from the concentration-response curve) increased by 116 
140% (from 0.67 nA ± 1.07 nA to 1.60 nA ± 0.47 nA) when the free [Ca2+] was raised from 117 
50 nmol/L to 200 nmol/L, the maximum current induced by 2ʹ-deoxy-ADPR increased only 118 
by 16% (from 14.3 nA ± 1.45 nA to 16.7 nA ± 0.74 nA, best-fit values ± SE). At 119 
(supraphysiological) saturating concentrations for Ca2+ and ADPR the open probability of 120 
human TRPM2 approaches a value of one21. It therefore seems likely that in intact cells 121 
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activation by 2ʹ-deoxy-ADPR is less sensitive to Ca2+, with the concentration-response for 122 
Ca2+ shifted to the left, allowing for higher open probabilities and larger whole cell currents at 123 
physiological Ca2+ concentrations. 124 
Biosynthetic pathways for 2ʹ-deoxy-ADPR 125 
Superagonist behavior has previously been observed with pharmacological modulators of 126 
ligand-gated ion channels usually having little or no resemblance to the natural ligands. 127 
However, 2ʹ-deoxy-ADPR is closely related to ADPR. Thus, we hypothesized that 2ʹ-deoxy-128 
ADPR might be an endogenous modulator of TRPM2.  129 
A conceivable endogenous pathway to 2ʹ-deoxy-ADPR would be the hydrolysis of 2ʹ-deoxy-130 
NAD by either CD38 or the PARP/PARG system. 2ʹ-Deoxy-NAD can be synthesized by 131 
nicotinamide mononucleotide adenylyltransferase (NMNAT, EC 2.7.7.1) catalyzing the 132 
condensation of β-nicotinamide mononucleotide (NMN) and 2ʹ-deoxy-ATP,  as has been 133 
shown for NMNAT from yeast22 and human NMNAT-123. There are three different isoforms 134 
of NMNAT with distinct subcellular localization that contribute to different NAD pools24. 135 
Here we demonstrate for the first time that NMNAT-2, the isoform that presumably maintains 136 
the cytoplasmic NAD pool24, also catalyzed the conversion of 2ʹ-deoxy-ATP and NMN to 2ʹ-137 
deoxy-NAD (Fig. 4a; Supplementary Fig. 6). At a saturating concentration of 500µmol/L β-138 
NMN the K0.5 for 2ʹ-deoxy-ATP is 3.28 mmol/L ± 0.55 mmol/L (Michaelis-Menten constant 139 
KM for ATP 611 µmol/L ± 31 µmol/L, both best-fit values ± SE). Interestingly, the enzyme 140 
did not only show cooperativity (Hill coefficient nH 1.4 ± 0.1, best-fit value ± SE) with regard 141 
to 2'-deoxy ATP, but was also inhibited by high concentrations of the substrate, which is 142 
clearly not the case for ATP (Fig. 4b).  143 
Next we explored potential pathways for generation of 2'-deoxy-ADPR via both the 144 
PARP/PARG and CD38 pathways. Since it was shown in isolated nuclei that 2'-deoxy-ADPR 145 
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was incorporated into poly-ADPR polymers of nuclear proteins25, we analyzed whether poly-146 
ADP ribosylated proteins actually contain 2'-deoxy-ADPR residues. Poly-ADP-ribosylated 147 
proteins were isolated from HEK293 cells previously exposed to H2O25,26. An increase of the 148 
amount of poly-ADP ribosylated proteins, compared to unstimulated controls was confirmed 149 
by western blot analysis (Supplementary Fig. 7, upper inset). The immunoprecipitate was then 150 
hydrolyzed by recombinant human PARG. Analysis of products by HPLC showed significant 151 
amounts of ADPR and a small amount of AMP, most likely due to spontaneous degradation 152 
of ADPR  Supplementary Fig. 7, central panel), but despite the high sensitivity of the method 153 
(40 fmol at signal-to-noise (S/N) ratio  ≥ 3) no 2'-deoxy-ADPR was detected (Supplementary 154 
Fig. 7, central and lower panel). Thus, it is unlikely that release of 2ʹ-deoxy-ADPR from poly-155 
ADP-ribosylated proteins by PARG significantly contributes to TRPM2 activation. 156 
Next we tested whether CD38 might produce 2'-deoxy-ADPR. CD38 is well known to be 157 
expressed as ecto-enzyme (type II orientation), but recently evidence for type III orientation 158 
with the active site facing the cytoplasm was presented27, thereby potentially allowing 159 
turnover of cytosolic 2ʹ-deoxy-NAD. Recombinant soluble human CD38 completely 160 
hydrolyzed 2'-deoxy-NAD to a product that co-eluted with chemically synthesized 2'-deoxy-161 
ADPR (Fig. 4c). Product identity was confirmed by spiking with authentic 2'-deoxy-ADPR 162 
(Supplementary Fig. 8a) and hydrolysis by pyrophosphatase to 2'-deoxy-AMP 163 
(Supplementary Fig. 8b). Further, type III CD38 enzyme activity, though small in comparison 164 
to ecto-enzyme (type II) CD38 enzyme activity, was clearly detected in Jurkat T cells (Fig 165 
4d). While in CD38-/- cells measurable NAD glycohydrolase was not detected (Fig. 4d, left), 166 
specific inhibition of ecto-CD38 by 2'-deoxy-2'-fluoro arabinosyl NAD (araF-NAD)28, 167 
forming a stable covalent inhibitor-CD38 complex, almost completely abolished type II CD38 168 
activity (Fig. 4d, middle, 1st araF-NAD addition). Permeabilization of such cells with saponin 169 
allowed to access type III CD38 and to determine its activity (Fig. 4d, right). Specificity was 170 
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demonstrated by a 2nd addition of araF-NAD fully blocking type III CD38 (Fig. 4d, right). 171 
Kinetic analysis using NAD vs 2'-deoxy-NAD as substrates resulted in 9.2-fold higher affinity 172 
of CD38 for 2'-deoxy-NAD and comparable values for maximal velocity Vmax 173 
(Supplementary Fig. 8c). Collectively, strong evidence is presented that 2'-deoxy-NAD serves 174 
as a substrate for type III CD38 to produce 2'-deoxy-ADPR, while 2'-deoxy-NAD can be 175 
produced from the abundant cellular metabolites nicotinamide mononucleotide and 2'-deoxy-176 
ATP by cytosolic NMNAT (Supplementary Fig. 9). 177 
2ʹ-Deoxy-ADPR and 2ʹ-deoxy-NAD present in Jurkat cells 178 
To detect endogenous 2ʹ-deoxy-ADPR and 2ʹ-deoxy-NAD in Jurkat T cells, we used two 179 
consecutive reversed phase (RP)-HPLC separations on C8 and C18 columns using a volatile 180 
ammonium acetate buffer to allow for subsequent high resolution mass spectrometry (Fig. 5). 181 
Fractions pre-fractionated on a C8 column (Fig. 5a) and co-eluting with 2ʹ-deoxy-ADPR and 182 
2ʹ-deoxy-NAD on a C18 column (Fig. 5b+c) showed molecular ions corresponding to 2ʹ-183 
deoxy-ADPR (observed mass [M-H]- 542.0722, calculated mass: 542.0695) and 2ʹ-deoxy-184 
NAD (observed mass [M-H]- 646.1104, calculated mass: 646.1069) (Supplementary Fig. 10 185 
a+b). The main electrospray ionization (ESI) fragmentation products of 2ʹ-deoxy-ADPR and 186 
2ʹ-deoxy-NAD, 2ʹ-deoxy-AMP ([M-H]- 330.0633) and 2ʹ-deoxy-ADP ([M-H]- 410.0304), 187 
were prominent in both samples. Since it is unlikely that both products co-eluted with 2ʹ-188 
deoxy-ADPR and 2ʹ-deoxy-NAD during two-dimensional HPLC, these molecular ions are 189 
most likely to result from fragmentation of 2ʹ-deoxy-ADPR and 2ʹ-deoxy-NAD during mass 190 
spectrometry. The HPLC system based on ammonium acetate eluents was suitable for 191 
quantification of endogenous 2ʹ-deoxy-NAD (Fig. 5c+g), amounting to 5.05 ± 0.58 192 
pmol/107 cells (mean ± SEM, n=12, significantly different from a theoretical median of 0, 193 
Wilcoxon Signed Rank Test). The concentration of 2ʹ-deoxy-NAD was not significantly 194 
affected by exposure of the cells to hydrogen peroxide (5.67 ± 0.78 pmol/107 cells, mean ± 195 
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SEM, n=11) (Fig. 5c+g). To investigate any role of CD38 in the synthesis of 2ʹ-deoxy-ADPR 196 
in Jurkat T cells, CD38 was knocked-out using CRISPR (Clustered Regularly Interspaced 197 
Short Palindromic Repeats)/Cas9 technology29,30. P10 membranes of the resulting CD38-/- cell 198 
line did not show NAD glycohydrolase activity and were negative for CD38 in western blot 199 
analysis (Supplementary Fig 11). Neither was the endogenous concentration of 2ʹ-deoxy-200 
NAD significantly affected by knock-out of CD38 nor by hydrogen peroxide stimulation (Fig. 201 
5 d+f+g). In addition, we also analyzed cellular ADPR and NAD contents under these 202 
conditions (Supplementary Fig 12). As expected, NAD was present in much higher quantities 203 
(7.58 ± 0.42 nmol/107 cells, mean±SEM, n=12), but was not affected by knockout of NAD 204 
glycohydrolase CD38 (6.42 ± 0.30 nmol/107 cells, mean±SEM, n=15). Exposure to hydrogen 205 
peroxide did, at least during the 5 min of the experiment, not affect NAD (p=0.78 for wild 206 
type and p=0.62 for CD38-/- cells). ADPR was found in quantities (292 ± 79 pmol/107 cells, 207 
mean±SEM, n=11) consistent with our previous results4, but was neither significantly affected 208 
by knockout of CD38 nor by exposure to hydrogen peroxide.  209 
In contrast to almost baseline-separated 2ʹ-deoxy-NAD (Fig. 5c+f), HPLC using volatile 210 
ammonium acetate buffer (ideally suited for subsequent mass spectrometry) did not allow for 211 
baseline separation of 2ʹ-deoxy-ADPR (Fig. 5b+e). Though 2ʹ-deoxy-ADPR was qualitatively 212 
identified (i) by its retention time, (ii) by using samples from cell extracts spiked with a small 213 
amount of authentic 2ʹ-deoxy-ADPR (Fig. 5b+e), and (iii) by mass spectrometry 214 
(Supplementary Fig. 10a), the separation on a C18 column was not sufficient to quantify 2ʹ-215 
deoxy-ADPR reliably (Fig. 5b+e). However, we noted that the peak containing 2ʹ-deoxy-216 
ADPR increased after stimulation with hydrogen peroxide. Further, comparison of the 217 
chromatograms of samples from wildtype (Fig. 5b) and CD38-/- cells (Fig. 5e) shows that the 218 
peak containing 2ʹ-deoxy-ADPR was absent in the samples from CD38-/- cells regardless of 219 
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whether they have been exposed to H2O2 or not, suggesting that 2ʹ-deoxy-ADPR is produced 220 
from 2ʹ-deoxy-NAD by CD38. 221 
Using ion-pair instead of conventional RP-HPLC, two consecutive separations on C8 and C18 222 
columns (Fig. 6) resulted in sufficient separation of endogenous 2ʹ-deoxy-ADPR for 223 
quantification (Fig. 6a, lower panel). Here, 2ʹ-deoxy-ADPR was identified using authentic 2ʹ-224 
deoxy-ADPR as standard or in a spiked sample (Fig 6a). Recovery of 2ʹ-deoxy-ADPR was 225 
determined using 1, N6-etheno-adenosine (Supplementary Fig 13). Any trials to identify 2ʹ-226 
deoxy-ADPR by mass spectrometry in this HPLC system failed due to the presence of the ion 227 
pair reagent in the collected samples; furthermore, several procedures tested to deplete the ion 228 
pair reagent were not successful. However, using this ion-pair RP-HPLC separations on C8 229 
and C18 columns, 2ʹ-deoxy-ADPR was detected in Jurkat cells and determined to be 230 
35 pmol/107 cells (median, interquartile range (IQR): 17 pmol/107 cells to 50 pmol/107 cells, 231 
significantly different from a theoretical median of 0, Wilcoxon Signed Rank Test). As 232 
hydrogen peroxide treatment results in TRPM2 activation, we then tested the impact of H2O2 233 
on the endogenous 2ʹ-deoxy-ADPR concentration (Fig. 6b+c). After 5 min the amount of 2ʹ-234 
deoxy-ADPR rose significantly by 2.71 fold to 95 pmol/107 cells (median, IQR: 42 235 
pmol/107 cells to 116 pmol/107 cells). 236 
Discussion 237 
It is widely accepted that TRPM2 can be activated downstream of reactive oxygen species 238 
like hydrogen peroxide10,31. Despite reports of direct activation of the channel by hydrogen 239 
peroxide32, this has mostly been attributed to the generation of ADPR by the consecutive 240 
action of PARP and PARG5,33. Especially during certain cell cycle phases, 2ʹ-deoxy-ADPR as 241 
an additional mechanism might contribute to this process: hydrogen peroxide-induced DNA 242 
damage can cause a replication arrest during S phase, which would result in an accumulation 243 
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of 2ʹ-deoxy-ATP, because deoxy-nucleoside triphosphates will no longer be consumed by the 244 
replication machinery. In addition, the activation of PARPs following DNA damage will 245 
result in consumption of NAD for poly-ADP ribosylation. The consequent drop in cellular 246 
NAD will increase its synthesis, which ultimately results in decreased cellular ATP pools. The 247 
increased ratio of 2ʹ-deoxy-ATP to ATP then facilitates synthesis of 2ʹ-deoxy-NAD by 248 
NMNAT and subsequent hydrolysis to 2ʹ-deoxy-ADPR by CD38. The latter reaction is 249 
preferred due to the 9.2-fold higher affinity of CD38 for 2'-deoxy-NAD, as compared to NAD 250 
(see Supplementary Fig. 8c). The increase in cellular 2ʹ-deoxy-ADPR then either mediates 251 
TRPM2 activation on its own or contributes to TRPM2 activation mediated by ADPR derived 252 
from PARP/PARG activity. 253 
How do the nucleotide determinations from cell extracts translate into cytosolic, or even sub-254 
plasmalemmal, concentrations? Assuming a mean diameter of Jurkat cells of 11.5 µm34, a 255 
cellular 2ʹ-deoxy-ADPR concentration of 4.4 µmol/L can be calculated. However, the 256 
lymphocyte is not simply a sphere filled with aqueous liquid, but contains solid material, e.g. 257 
organelles, DNA, proteins. This solid portion is difficult to calculate, but well known for 258 
Jurkat cells is the nucleus volume, amounting to 55% of the total volume34. Using this portion 259 
to distinguish the cytosolic from the intra-nuclear space, the cytosolic concentration of 2ʹ-260 
deoxy-ADPR amounts to 9.8 µmol/L, a value found in the lower part of the concentration-261 
response curve (Fig. 2). Upon stimulation by hydrogen peroxide this cytosolic concentration 262 
within 5 min rises to 26.6 µmol/L. If we further assume that the concentration of 2ʹ-deoxy-263 
ADPR in the cytosol is not evenly distributed, but is increased at the site of its biosynthesis, 264 
the sub-plasmalemmal space where the catalytic center of type III CD38 is localized27, then 265 
the local concentrations are readily in the dynamic range of the concentrations response 266 
curve(s) shown in Fig. 2, especially at slightly elevated free cytosolic Ca2+ concentrations, 267 
e.g. 200 nM (Fig. 2c). Besides 2ʹ-deoxy-ADPR, we also established the presence of 268 
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endogenous 2ʹ-deoxy-NAD, the potential precursor of 2ʹ-deoxy-ADPR. The cytosolic 269 
concentration of 2ʹ-deoxy-NAD is low at 1.41 µmol/L, in comparison to the cellular 270 
concentration of NAD (955 µmol/L). This indicates that 2ʹ-deoxy-NAD represents a 271 
nucleotide with specialized function(s), very much in contrast to NAD that serves as (co)-272 
substrate for a plethora of enzymatic reactions. The kinetic parameters obtained for NMNAT-273 
2 (Fig. 2c) suggest that inside the cell mainly ATP is used to maintain the cellular NAD pool. 274 
However, upon stimulation with hydrogen peroxide, small amounts of 2ʹ-deoxy-ATP appear 275 
to flux via 2ʹ-deoxy-NAD into 2ʹ-deoxy-ADPR; substrate inhibition of NMNAT-2 by 2ʹ-276 
deoxy-ATP, but not ATP, indicates that the pathway towards 2ʹ-deoxy-ADPR is a highly 277 
regulated process. It has not escaped our notice that the presence of endogenous 2ʹ-deoxy-278 
NAD also in principle presents the possibility for generation of 2ʹ-deoxy-cADPR by CD38, in 279 
addition to 2ʹ-deoxy ADPR. While 2ʹ-deoxy-cADPR was shown to be equipotent to cADPR 280 
in Ca2+ signaling in sea urchin35, like its 3ʹ-deoxy congener, it was not active in Jurkat T 281 
cells36 excluding the need to consider 2ʹ-deoxy-cADPR more widely in a signaling context. 282 
Our results might solve an important conceptual problem concerning activation of TRPM2: 283 
Cellular NAD serves many functions, most prominently as redox coenzyme, as co-substrate 284 
for sirtuins, and as precursor for nicotinamide adenine dinucleotide phosphate (NADP) and 285 
the second messengers cyclic adenosine diphosphoribose (cADPR) and nicotinic acid adenine 286 
dinucleotide phosphate (NAADP, reviewed in24). NAD depletion appears therefore 287 
incompatible with life and has been shown to ultimately result in cell death37. We therefore 288 
consider it unlikely that during physiological activation the amount of ADPR necessary for 289 
TRPM2 activation, especially at resting Ca2+ concentrations, is generated by turnover of 290 
nuclear, cytosolic or mitochondrial NAD pools. In contrast, a small cytosolic pool of 2ʹ-291 
deoxy-NAD might be maintained, for instance by NMNAT, independently of NAD, since 2ʹ-292 
deoxy-NAD can neither be phosphorylated by NAD kinase to yield 2ʹ-deoxy-NADP nor is it a 293 
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good substrate for NAD dependent dehydrogenases22,38,39. Thus, formation of 2ʹ-deoxy-ADPR 294 
from 2ʹ-deoxy-NAD by type III CD38 does not interfere with energy metabolism and other 295 
NAD functions. Previous work demonstrating that CD38 hydrolyzed 2ʹ-deoxy-NAD with 296 
similar Vmax as NAD40 is confirmed here; however, a 9.2-fold higher affinity for 2ʹ-deoxy-297 
NAD as compared to NAD was determined (Supplementary Fig. 8c). Thus, we present here a 298 
possible mechanism for the generation of 2ʹ-deoxy-ADPR via conversion of cytosolic 2ʹ-299 
deoxy-NAD by CD38 in a type III orientation. However, since the endogenous concentration 300 
of 2ʹ-deoxy-NAD is small and the relative activity of CD38 in the type III orientation that we 301 
observed was low, generation of 2ʹ-deoxy-ADPR may be accomplished via alternative 302 
pathways. 303 
Taken together, we demonstrate that 2ʹ-deoxy-ADPR is the most efficient endogenous agonist 304 
of TRPM2 described to date. In addition, 2ʹ-deoxy-ADPR appears to be the first superagonist 305 
for an ion channel that can be synthesized by the enzymatic machinery of most cell types. Our 306 
results suggest the possibility that TRPM2 can be activated in context-specific manner. In 307 
pathological cell death in neurodegenerative diseases41, stroke42, or myocardial infarction43, 308 
ADPR may be generated by PARP/PARG33 or by CD38 thereby not only triggering TRPM2 309 
activation, but also depleting cellular NAD and ATP pools. In contrast, since physiological 310 
processes, e.g. neutrophil chemotaxis, require an intact cytoplasmic NAD pool, 2ʹ-deoxy-311 
ADPR may activate TRPM2 without consumption of NAD, thus acting independently of 312 
energy metabolism. Taken together, the confluence of properties associated with 2ʹ-deoxy-313 
ADPR may point to a physiological role for the molecule as a novel second messenger 314 
activating TRPM2. 315 
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Figure legends for main text 453 
Fig. 1 ADPR analogues activate TRPM2 in whole cell patch clamp experiments. Outward 454 
currents at +15 mV were recorded as detailed in Methods section. Pipette concentration for 455 
ADPR and ADPR analogues was 100 µmol/L in most cases; exceptions are indicated.  Data 456 
for 30 µmol/L 2ʹ-deoxy-ADPR are from the same experiment as in Fig 2a. Shown are 457 
maximum currents from individual patched cells, with the total number of cells indicated. 458 
Recordings have usually been performed on multiple days. The median current from all cells 459 
of one condition is indicated by a horizontal line. Since in some cases the number of data 460 
points was too small to test for normality, data were analyzed by a nonparametric one-way 461 
ANOVA (Kruskal−Wallis test) followed by comparison against buffer control, applying 462 
Dunn’s correction for multiple testing. Results significantly different from buffer control 463 
(p<0.05) are indicated by an asterisk. The pipette solution for squaryl and triazole compounds 464 
contained 0.1% DMSO; thus, 0.1% DMSO was also used  for control conditions. (ADPR - 465 
adenosine 5ʹ-diphosphoribose; AMP - adenosine 5ʹ-monophosphate; ASqR - adenosine 466 
squaryl ribose; ATPR - adenosine 5ʹ-triphosphate ribose; IDPR - inosine-5ʹ-diphosphoribose; 467 
Sal-AMS - salicyl-adenosine monosulfamide, 8-pCPT-AMP - 8-(4-468 
Chlorophenylthio)adenosine-5ʹ-O-monophosphate; 8-Ph-ATrR - 8-Phenyl-adenosine-1,4-469 
triazole ribose). Abbreviations for ligands evaluated are consistent with those in reference 13. 470 
Analogue structures shown are examples, see Supplementary Fig. 1-4 for all structures. 471 
 472 
Fig. 2 Modifications of the proximal ribose affect the ability of ADPR to activate 473 
TRPM2. a, Concentration response relationship for activation of TRPM2 by ADPR, 2ʹ-474 
deoxy-ADPR, 3ʹ-deoxy-ADPR and 2ʹ-phospho-ADPR in HEK293 cells expressing hTRPM2. 475 
Pipette solution contained 200 nmol/L free Ca2+. In the NMDG-based bath solution TRPM2 476 
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showed characteristic reversal potential and outward rectification (Suppl. Fig. 5a). Currents 477 
are displayed as mean±SEM (n= 6–12 for ADPR, 5–6 for 2ʹ-phospho-ADPR, 5–12 for 2ʹ-478 
deoxy-ADPR, 5–9 for 3ʹ-deoxy-ADPR). b, Concentration response relationship for activation 479 
of endogenous TRPM2 in Jurkat cells. In the NaCl-based bath solution the current showed the 480 
reversal potential and I-V relationship of a non-selective cation channel (Suppl. Fig. 5b). 481 
Currents are displayed as mean ±SEM (n=2–13 for ADPR, 2–21 for 2ʹ-deoxy-ADPR). Result 482 
from a single cell with  250 µmol/L 2ʹ-deoxy ADPR in parenthesis (not included in the 483 
concentration response curve). The current axis is shown in reversed orientation to facilitate 484 
comparison with panel a. c, Ca2+-dependence of TRPM2 activation by ADPR and 2ʹ-deoxy 485 
ADPR. Concentration response curves for ADPR and 2ʹ-deoxy-ADPR with 50 nmol/L free 486 
Ca2+ in the pipette solution are shown in addition to the curves with 200 nmol/L from panel a. 487 
Currents are displayed as mean±SEM (at 50 nM Ca2+ n=2–6 for ADPR, 3–7 for 2ʹ-deoxy-488 
ADPR for 200 nM Ca2+ see panel a). In all panels n refers to the number of cells recorded for 489 
the respective condition, recordings have been performed over multiple days. 490 
 491 
Fig. 3 Impact of 2ʹ-deoxy-ADPR on hTRPM2 in excised inside-out patches. a, Current 492 
steps of hTRPM2 activated by 100 µmol/L ADPR at different potentials. b, I-V relationship 493 
from patches containing TRPM2 wt or TRPM2 T5L activated by either 100 µmol/L ADPR  494 
or 2'-deoxy-ADPR in the presence of 1 µmol/L free Ca2+ (n=6-17 patches for TRPM2 wt and 495 
n=2–3 patches for TRPM2 T5L). c, Single channel slope conductance γ obtained by linear 496 
regression of the data in panel b. (unpaired, two-tailed T-tests of the mean±SEM obtained 497 
from linear regression, p values are indicated) d, Representative continuous recordings of 498 
excised inside out patches with the bath solution containing either 100 µmol/L ADPR or 2ʹ-499 
deoxy-ADPR. e-h, Quantitative analysis of continuous recordings from excised inside-out 500 
patches e, Histograms of time to inactivation of wild type TRPM2 after activation by ADPR 501 
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or 2ʹ-deoxy ADPR with exponential fit. f, Decay constants for the time to inactivation. (extra 502 
sum-of-squares F-Test, p=0.0012). g, Average open probability after activation by ADPR or 503 
2ʹ-deoxy-ADPR. Whiskers indicate min and max, horizontal bar represents the median 504 
(Mann-Whitney test, p < 0.0001). h, Maximum number of simultaneously active channels in 505 
an excised patch after application of either ADPR or 2ʹ-deoxy-ADPR. (unpaired two-tailed T-506 
test, < 0.0001). a-h If not indicated otherwise, data are shown as mean±SEM. Numbers 507 
indicated in the bars refer to the number of patches recorded, usually over multiple days. 508 
Significant differences are indicated by asterisks. 509 
 510 
Fig. 4 NMNAT-2 and CD38 synthesize 2ʹ-deoxy-ADPR in vitro. a, β-NMN and 2ʹ-deoxy-511 
ATP were incubated with recombinant hNMNAT-2 and reaction products analyzed by HPLC. 512 
2ʹ-deoxy-AMP and 2ʹ-deoxy-ADP were impurities contained in commercial 2ʹ-deoxy-ATP. b, 513 
Saturation plot for ATP and 2ʹ-deoxy-ATP as substrates of NMNAT-2; β-NMN was used at 514 
290µmol/L for both ATP and 2ʹ-deoxy-ATP. Initial reaction rate was calculated from the 515 
amount of product formed, determined by HPLC (mean±SD (n=3 independent experiments 516 
with the concentration range shown for ATP, for 2ʹ-deoxy-ATP 3 additional experiments were 517 
performed for 3 mM, 5 mM, 7 mM and 9 mM, therefore n=6 for 3 mM and 9 mM)). Data for 518 
ATP were fitted to a Michaelis-Menten model. Data up to 3 mmol/L 2ʹ-deoxy-ATP were 519 
fitted to a Hill model. At higher concentrations the reaction rate dropped rapidly, indicating 520 
substrate inhibition (dashed line). c, Recombinant hCD38 hydrolyzed 2ʹ-deoxy-NAD (from 521 
panel a) to yield the TRPM2 agonist 2ʹ-deoxy-ADPR (a+c are representative for three 522 
independent experiments). d, CD38 activity was determined by incubation of Jurkat cells with 523 
1,N6-etheno-NAD and HPLC analysis of product 1,N6-etheno-ADPR at different time points. 524 
To analyze CD38 activity in type III orientation (red symbols), CD38 activity on the cell 525 
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surface was inhibited by covalently bound araF-NAD (blue symbols turned into gray). To 526 
obtain access to type III CD38, the plasma membrane was selectively permeabilized using 527 
saponin. After determination of type III CD38 activity, cells were incubated with araF-NAD 528 
again (red symbols turned into gray). Data are shown as mean±SEM. The number of 529 
experiments is indicated. For conditions tested in a one-way ANOVA for repeated 530 
measurements, using Tukey’s corrections for multiple testing, the corrected p values are 531 
shown.  532 
 533 
Fig. 5 The increase in 2ʹ-deoxy-ADPR in Jurkat cells exposed to hydrogen peroxide 534 
depends on CD38. Wild type and CD38-/- Jurkat cells were either exposed to 100 µmol/L 535 
H2O2 for 5 min or left unstimulated. a+d Deproteinized extracts from cell samples were 536 
separated by RP-HPLC on Phenomenex Luna C8 column and fractions co-eluting with 537 
authentic ADPR, NAD, 2ʹ-deoxy-ADPR or 2ʹ-deoxy-NAD were collected. b+c+e+f Fractions 538 
from the pre-fractionation on C8 column were subjected to a second dimension of RP-HPLC 539 
on Multohyp BDS-C18 5µ column. To correctly assign peaks, each sample was split and one 540 
half was spiked with the respective nucleotide (gray tracings). Representative chromatograms 541 
for each condition are shown. Since we could not achieve baseline separation for 2ʹ-deoxy-542 
ADPR, it was not analyzed quantitatively, however, the peak of 2ʹ-deoxy-ADPR clearly 543 
increased upon hydrogen peroxide stimulation. In the chromatograms from CD38-/- cells the 544 
respective peak was not detected, regardless of stimulation. g, Quantitative analysis of the 545 
impact of H2O2 on intracellular 2ʹ-deoxy-NAD. Independent experiments were initiated on 3 546 
separate days over the course of one month, with each experiment consisting of multiple 547 
parallel cell preparations. 2–6 data points were obtained per experimental day. Results from 548 
single experiments are indicated as filled circles (horizontal lines indicate the mean) with the 549 
same shade of gray signifying individual experiments from a single day. Data are normally 550 
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distributed in each group. Analysis by one-way ANOVA did not reveal significant differences 551 
for 2ʹ-deoxy-NAD (p=0.074).  552 
 553 
Fig. 6 Concentration of 2ʹ-deoxy ADPR in Jurkat cells increased after exposure to 554 
hydrogen peroxide. a, Deproteinized cell extracts from either unstimulated Jurkat cells or 555 
Jurkat cells exposed to 100 µmol/L H2O2 were applied to a Phenomenex Luna C8 column and 556 
a fraction co-eluting with chemically synthesized 2ʹ-deoxy ADPR (Rt between 24 and 25 min) 557 
was collected a + b, The fractions were further chromatographed on a Multohyp BDS-C18 5µ 558 
column. To confirm identity of the peak co-eluting with standard  2ʹ-deoxy ADPR (dashed 559 
tracing), samples were also spiked with 15.6 nmol 2ʹ-deoxy ADPR (gray tracing). The slight 560 
enhancement of the spiked peak is in agreement with the amount of 2ʹ-deoxy-ADPR added as 561 
spike (see standard trace for comparison). d, Quantitative analysis of the impact of H2O2 on 562 
intracellular 2ʹ-deoxy ADPR (per 107 cells). Results from single experiments are indicated as 563 
gray symbols (horizontal lines indicating median value) with symbols of same shape and gray 564 
level signifying experiments from the same day. The number of independent preparations and 565 
the number of days (12 samples from 3 days for H2O2 stimulated cells vs 47 samples from 7 566 
days for unstimulated cells) are indicated in the chart. Due to non-normal distribution, data 567 
were analyzed by a nonparametric Mann-Whitney test.  568 
 569 
Online Methods 570 
Chemical Synthesis and Purification of ADPR Analogues 571 
Chemical synthesis, purification and characterization of 2ʹ-deoxy-ADPR, 3ʹ-deoxy-ADPR and 572 
all other non-commercial ADPR analogues, apart from hydroxyl-ethoxy-ethyl-ASq, was as 573 
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described previously13,44,35. Analogue identity was confirmed by 1H-NMR and HRMS. Purity 574 
was checked by HPLC (>95%) and re-checked after storage. 575 
Synthesis of hydroxyl-ethoxy-ethyl-ASq 576 
3-(2-(2-hydroxyethoxy)ethylamino)-4-ethoxycyclobut-3-ene-1,2-dione 577 
To a solution of 2-(2-aminoethoxy)ethanol (95 µL, 0.951 mmol) and DIPEA (81 μL, 0.467 578 
mmol) in EtOH (8 mL) was added diethylsquarate (128 μL, 0.865 mmol). After 1h, the 579 
solvent was removed under reduced pressure and the residue was purified on an Isco 580 
chromatographic system (DCM-acetone, 8:2 v/v) to yield the desired product as a colorless oil 581 
(165 mg, 91%). 1H (400 MHz, d4-MeOH) δ 4.79 (q, 2H, J = 7.1 Hz, OCH2-Me), 3.85-3.61 582 
(m, 8H, 4 x CH2) and 1.51 (t, 3H, J = 7.1 Hz, CH3). 13C (100 MHz, d4-MeOH) δ 189.9 (C-2), 583 
184.9 (C-1), 177.9 (C-3), 175.1 (C-4), 73.5, 70.9 (both CH2), 70.7 (Et: CH2), 62.2, 45.5 (both 584 
CH2) and 16.2 (Et: CH3). HRMS (ES+) calcd for C10H16NO5 230.1023 (MH)+ found 585 
230.1031.  586 
3-(2′,3′-O-Isopropylidene-5′-amino-5′-deoxyadenosine)-4-(2-(2-hydroxyethoxy)ethyl- 587 
amino)cyclobut-3-ene-1,2-dione 588 
To a solution of 3-(2-(2-hydroxyethoxy)ethylamino)-4-ethoxycyclobut-3-ene-1,2-dione (60 589 
mg, 0.287 mmol) and DIPEA (27 μL, 0.154 mmol) in EtOH-DMF (1:1 v/v, 1 mL) was added 590 
2′,3′-isopropylidene-5′-amino-5′-deoxyadenosine (96 mg, 0.315 mmol). After 26h, the solvent 591 
was removed under reduced pressure and the residue was purified on an Isco chromatographic 592 
system (DCM-MeOH, 8:2 v/v) to yield the desired product as a white foam (104 mg, 74%). 593 
1H (400 MHz, d6-DMSO) δ 8.30 (s, 2H, H-8 and H-2), 6.24 (d, 1H, J1′,2′ = 2.6 Hz, H-1′), 5.55 594 
(dd, 1H, J2′,3′ = 6.4 and J2′,1′ = 2.6 Hz, H-2′), 5.16 (dd, 1H, J3′,2′ = 6.4 and J3′,4′ = 3.7 Hz, H-3′), 595 
4.44-4.41 (m, 1H, H-4′), 4.07-4.04 (m, 1H, H-5′a), 3.94 (dd, 1H, J5′b,5′a = 14.1 and J5′b,4′ = 6.6 596 
Hz,  H-5′b), 3.78 (brs, 2H, CH2-O), 3.72-3.70 (br, 2H, CH2-NH), 3.64 (brs, 2H, CH2-O), 3.61-597 
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3.59 (m, 2H, CH2-OH), 1.65 (s, 3H, CH3) and 1.44 (s, 3H, CH3). 13C (100 MHz, d6-DMSO) δ 598 
184.2 (C-2), 183.3 (C-1), 169.6 (both C=C), 157.6 (C-6), 154.3 (C-2), 150.3 (C-4), 142.0 (C-599 
8), 120.7 (C), 115.9 (C-5), 91.5 (C-1′), 87.0 (C-4′), 85.1 (C-2′), 82.9 (C-3′), 73.6, 71.4, 62.1, 600 
46.7 (all CH2), 45.1 (C-5′), 27.6 and 25.6 (both CH3). HRMS (ES+) calcd for C21H28N7O7 601 
490.2045 (MH)+ found 490.2027. 602 
3-(5′-amino-5′-deoxyadenosine)-4-(2-(2-hydroxyethoxy)ethylamino)cyclobut-3-ene-1,2-dione 603 
(23) 604 
3-(2′,3′-O-Isopropylidene-5′-amino-5′-deoxyadenosine)-4-(2-(2-hydroxyethoxy)ethylamino)- 605 
cyclobut-3-ene-1,2-dione (80 mg, 0.163 mmol) was stirred in a 75% aq. TFA solution (5 mL) 606 
at rt for 1h. The solvents were evaporated under reduced pressure and the residue co-607 
evaporated with MeOH to remove any residual TFA. The remaining residue was purified on 608 
an Isco purification system (DCM-MeOH, 8:2 v/v) to yield the desired compound as a white 609 
solid (60 mg, 82%). 1H (400 MHz, d6-DMSO) δ 8.39 (s, 1H), 8.22 (s, 1H), 7.57 (br s, 2H), 610 
7.37 (br s, 2H, NH2), 5.97 (d, 1H, J1′,2′ = 5.8 Hz, H-1′), 5.62 (d, J = 6.1 Hz, 2′-OH), 5.44 (d, J 611 
= 4.8 Hz, 3′-OH), 4.75 (ddd, 1H, J2′,3′ = 6.4, J2′,OH = 6.1, J2′,1′ = 5.8 Hz, H-2′), 4.67 (t, J = 5.3, 612 
OH), 4.21 (ddd, 1H, J3′,2′ = 6.4, J3′,OH = 4.8, J3′,4′ = 4.0 Hz, H-3′), 4.08-4.05 (m, 2H, H-4′, H-613 
5′a), 3.85-3.80 (m, 1H, H-5′b), 3.69 (brs, 2H, CH2-O), 3.56-3.49 (m, 6H, 3 × CH2). 13C (125 614 
MHz, d6-DMSO) δ 182.6 (C-2), 182.4 (C-1), 167.8 (both C=C), 156.1 (C-6), 152.7 (C-2), 615 
149.4 (C-4), 139.8 (C-8), 119.2 (C-5), 87.4 (C-1′), 83.6 (C-4′), 72.7 (C-2′), 72.1 (CH2), 70.8 616 
(C-3′), 70.0, 60.1 (both CH2), 45.5 (C-5′), 43.2 (CH2). HRMS (ES+) calcd for C18H24N7O7 617 
450.1737 (MH)+ found 450.1730. 618 
 619 
Commercial ADPR Analogues 620 
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2ʹ-phospho-ADPR (15), 1,N6-etheno-ADPR (12), and 8-(4-Chlorophenylthio)adenosine-5ʹ-621 
mono-phosphate (8-pCPT-AMP, 32) were purchased from Biolog. 622 
Cell Culture 623 
Jurkat subclone JMP with high expression of CD3 was originally generated at University of 624 
Erlangen, Medical Faculty, Erlangen, Germany. They were recently authenticated as Jurkat by 625 
short tandem repeats (STR) profiling and tested negative for contamination with rodent cells 626 
(DSMZ service for the authentication of human cell lines).  Jurkat cells were cultured as 627 
described before45. Briefly, cells were kept in RPMI-1640 with GlutaMax-I and 25 mM 4-(2-628 
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) supplemented with 7.5% newborn 629 
calf serum (FCS) and penicillin (100 units/mL)/streptomycin (100 µg/mL). Cell density was 630 
kept between 0.3x106 and 1.0x106/ml. For determination of endogenous concentrations of 2ʹ-631 
deoxy-ADPR which required large amounts of cells, Jurkat cells were cultivated in spinner 632 
bottles at a cell density of up to 1.0x106 cells/mL.  633 
HEK293 Tet-On cells were obtained from Clontech/Takara. Wild type HEK293 cells were 634 
kindly provided by Prof. Dr. Manfred Jücker (Department of Biochemistry and Signal 635 
Transduction, University Medical Centre Hamburg-Eppendorf, Germany). HEK293 cells 636 
were kept in DMEM medium with 4.5 g/L D-glucose and without pyruvate supplemented 637 
with 10% fetal calf serum, 100 units/mL penicillin, and 100 µg/mL streptomycin. For 638 
maintenance of HEK293 cell lines TRPM2#24 and EGFP#8 400 µg/mL G418-sulfate was 639 
added to the medium. For the maintenance of HEK293 Tet-On cell line expressing the 640 
TRPM2 T5L mutant medium was supplemented with 100 µg/mL G418 sulfate and 25 µg/mL 641 
hygromycin B. All cells were kept at 37°C and 5% CO2. HEK293 cells are a well-established 642 
system for the electrophysiological characterization of recombinant ion channels. They 643 
express very little endogenous ion channels that might confound measurements and patch 644 
clamp experiments are straightforward since cells tend to seal very well. To avoid the risk of 645 
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using cross-contaminated cells the parental wild type HEK293 cells and the HEK293 Tet-On 646 
cell line expressing the T5L mutant of hTRPM2 were authenticated by STR profiling and 647 
tested negative for contamination with rodent cells (DSMZ service for the authentication of 648 
human cell lines). All cells were tested for mycoplasma contamination on a regular basis 649 
using an enzymatic assay (MycoAlert™ Mycoplasma Detection Kit, Lonza). 650 
Generation of HEK293 Cell Lines 651 
Generation of HEK293 cells with stable expression of hTRPM2 and EGFP (TRPM2 #24) has 652 
been described before13. The complete open reading frame of wild type hTRPM2 was 653 
amplified from the expression vector pIRES2-EGFP-TRPM2 described previously45 using the 654 
primers 5ʹ-GGAATTCCGCCACCATGGAGCCCTCAGCCCTG-3ʹ and 5ʹ-655 
TACTGTCGACTCAGTAGTGAGCCCC-3ʹ. EcoRI and SalI sites in the primers allowed for 656 
integration of the amplicon into the respective sites of the multiple cloning site of pTRE-tight 657 
(Clontech/Takara). The mutation T5L described by Tóth and coworkers20 was introduced by 658 
QuikChange mutagenesis (Stratagene/Agilent) using the primers 5ʹ-659 
GGCCAGATCCCGCTGGACGAGATCGACGGTGTGAACTTC-3ʹ and 5ʹ-660 
GAAGTTCACACCGTCGACTCGTCCAGCCGGGATCTGGCC-3ʹ. The complete open 661 
reading frame was confirmed by DNA sequencing (MWG Eurofins). HEK 293 Tet-On cells 662 
(Clontech/Takara) were co-transfected with pTRE-tight-TRPM2 T5L and pTK-Hyg 663 
(Clontech/Takara). Transfectants were selected by adding 25 µg/mL hygromycin B to the 664 
culture medium. Clonal cell lines for further analysis were generated from surviving cells by 665 
limiting dilution and chosen according to their response to hydrogen peroxide as described 666 
before13. While two clones showed a calcium signal in response to hydrogen peroxide, neither 667 
was inducible by doxycycline. Excised inside/out patches from both clones showed ADPR 668 
inducible currents with a higher single channel conductance than wild type TRPM2 as was 669 
expected for the T5L mutant. 670 
 29 
 
 
Whole Cell Patch Clamp Analysis of TRPM2 Activation 671 
Whole cell patch clamp experiments were performed as described previously13,46. Briefly, 672 
HEK293 cells with stable expression of human TRPM2 were seeded to 35 mm dishes. The 673 
day after medium was removed and replaced by bath solution (140 mM N-methyl-D-674 
glucamine (NMDG), 5 mM KCl, 3.3 mM MgCl2, 1 mM CaCl2, 5 mM D-glucose, 10 mM 675 
HEPES, pH 7.4 adjusted with HCl). Patch pipettes with a resistance of 1.5 to 3.5 MΩ were 676 
pulled from thin-walled 1.5 mm diameter borosilicate (1.10 mm x 1.50 mm x 80 mm) glass 677 
capillaries and filled with pipette solution (120 mM KCl, 8 mM NaCl, 1 mM MgCl2, 10 mM 678 
HEPES, 10 mM ethylene glycol-bis(β-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA), 679 
the concentration of free Ca2+ ions in the pipette solution was buffered to 50 nM or 200 nM 680 
by addition of either 2.3 mM or 5.6 mM CaCl2 as calculated by Maxchelator: 681 
http://maxchelator.stanford.edu/CaEGTA-NIST.htm). Currents were compensated for fast and 682 
slow capacity transients and recorded using an EPC10 amplifier and PatchMaster software 683 
(HEKA Elektronik). Series resistance was compensated by 70%. Voltage ramps from –85 mV 684 
to +20 mV in 140 ms were applied every 5 s over a period of 450 s starting from a holding 685 
potential of –50 mV. For analysis the maximum outward current at +15 mV during the course 686 
of experiment was extracted from all experiments. In the NMDG-based bath solution the I-V 687 
curve of TRPM2 showed characteristic reversal potential and outward rectification 688 
(Supplementary Results, Supplementary Fig. 5a), facilitating differentiation between 689 
activation of the non-selective cation channel and leaky cells/patches. If the patch ruptured 690 
before peak current was obtained or if significant changes in series resistance occurred during 691 
the measurement, recordings were excluded from analysis. 692 
Jurkat cells were seeded to 35 mm dishes coated with poly-L-Lysine (MW 70–150kDa, 693 
Sigma Aldrich). After cells had adhered to the dish, medium was removed and replaced by 694 
bath solution (140 mM NaCl, 2 mM MgCl2, 2 mM CaCl2, 5 mM KCl, 10 mM HEPES, and 5 695 
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mM glucose adjusted to pH 7.4 with NaOH). Pipettes were prepared as described above and 696 
filled with pipette solution (140 mM KCl, 2 mM MgCl2, 2.5 mM EGTA, and 10 mM HEPES 697 
adjusted to pH 7.4 with KOH, the concentration of free Ca2+ ions in the solution was buffered 698 
to 50 nM by addition of 0.59 mM CaCl2 as calculated by MaxChelator). Currents were 699 
recorded as described above. Voltage ramps from –85 mV to +65 mV in 200 ms were applied 700 
every 10 s over a period of 300 s starting from a holding potential of -60 mV. 701 
Electrophysiological Recordings from Excised Inside/Out-Patches 702 
Cells with stable expression of either wild type hTRPM2 or hTRPM2 T5L were seeded to 703 
35 mm dishes 24–48 h before use. Before the experiments medium was exchanged for a 704 
buffer based on sodium gluconate (140 mmol/L Na gluconate, 2 mmol/L MgCl2, 7.6 mmol/L 705 
CaCl2, 10 mmol/L EGTA, 10 mM HEPES pH7.2, free Ca2+ concentration 1 µmol/L). Patch 706 
pipettes with resistances of 10–15 MΩ were pulled from thick-walled borosilicate glass 707 
capillaries (0.86 mm x 1.50 mm x 80 mm) using a Sutter P-97 and filled with the same 708 
solution (symmetrical solutions). 100 nmol/L Tetrodotoxin (TTX) was added to the pipette 709 
solution to block endogenous voltage-gated sodium channels47. For activation of the channel 710 
either ADPR or 2ʹ-deoxy-ADPR was added to the bath solution. After excision of a patch 711 
with one or a few channels the fast capacity transients were compensated. For the 712 
determination of the average open probability the patch membrane was held at a potential of –713 
60 mV and the current was continuously recorded for a maximum of 30 min. For the 714 
determination of the slope conductance the potential across the patch membrane was 715 
increased by 20 mV steps every 20 s starting from –60 mV with a delay of 100 ms between 716 
steps. Data were sampled at 10 kHz and recorded to disk using the EPC10 amplifier and 717 
PatchMaster software (v2.32, HEKA Elektronik). For analysis of the single channel data 718 
recordings were filtered to remove 50 Hz mains hum by an electrical interference filter and 719 
low-pass-filtered (1 kHz) to remove high-frequency noise. To determine single channel 720 
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conductance Gaussian distributions were fitted to current histograms of the recordings and 721 
voltage steps were calculated as difference between the centers of the distributions. To 722 
determine average open probabilities continuous recordings were filtered and base-line 723 
corrected and exported to a script for trapezoid integration of the area under the curve written 724 
in Python (www.python.org, v2.7) and using the numpy/scipy libraries (www.scipy.org , 725 
numpy v1.8.1 and scipy v0.12.0) for numerical computations. At points of permanent 726 
inactivation of channels the recording was split into sections and the sections were separately 727 
integrated. The resulting integrals were divided by number of channels, duration and average 728 
height of voltage steps at –60 mV. The number of simultaneously open channels in a patch 729 
(Fig 3h) was determined either from the steps in the recording or for recordings where 730 
identification of individual states was not possible the number of channels was calculated by 731 
dividing peak current by single channel current for –60 mV. For display purposes (Fig 3a+d) 732 
data was filtered with a 100 Hz low pass filter and down-sampled by a factor of 10. 733 
Production of Recombinant Human CD38 734 
A fragment of the open reading frame of human CD38 encoding amino acids P44 to I300 was 735 
amplified using the primers 5ʹ-736 
ATGGTACGTCTCAGGCCCCGAGGTGGCGCCAGCAGTG-3ʹ and 5ʹ-737 
ATGGTACGTCTCAGCGCTGATCTCAGATGTGCAAGATGAATC-3ʹ. The amplicon was 738 
digested with Esp3I and inserted into the BsaI site of the multiple cloning site of the 739 
eukaryotic expression vector pEXPR-iba42 (Iba). The resulting reading frame encodes an N-740 
terminal BM40 signal sequence followed by a 6xHis-Tag, the extracellular part of CD38 and 741 
a C-terminal Strep-Tag. This open reading frame was confirmed by DNA sequencing (MWG 742 
Eurofins). HEK293 cells were transfected with the expression vector and transfectants were 743 
selected by addition of 400 µg/mL G418-sulfate to the culture medium. The bulk of surviving 744 
cells was continuously kept as described above and the supernatant medium was collected 745 
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each time cells were sub-cultured. Soluble recombinant CD38 secreted by the cells was 746 
purified from the pooled supernatant by affinity chromatography using Ni-NTA agarose 747 
(Qiagen). Imidazole was removed from elution fractions by dialysis and the protein solution 748 
concentrated by ultrafiltration. 749 
Enzymatic Synthesis of 2’-deoxy-NAD 750 
5 mmol/L β-NMN and 5 mmol/L 2ʹ-deoxy ATP were incubated at 37°C with 1 µg/mL 751 
recombinant human NMNAT-2 (R&D Systems) overnight. The enzyme was removed 752 
afterwards by passing the sample through a centrifugal filter device with 10 kDa cutoff. The 753 
sample volume was reduced using a SpeedVac evaporator. Separation of the product 2’-754 
deoxy-NAD from byproducts and remaining substrates was achieved by HPLC using a 755 
250 mm×10 mm Luna C8 5 µm column (Phenomenex) equipped with a 10 mm×10 mm guard 756 
cartridge containing a C8 ODS filter element (Phenomenex) at a flow rate of 2.5 mL/min with 757 
the buffer (50 mmol/L ammonium acetate, 0.05% acetic acid, pH 5.4) containing increasing 758 
amounts of methanol as outlined below. The fraction co-eluting with chemically synthesized 759 
2'-deoxy-NAD was collected, dried using a SpeedVac evaporator, reconstituted in water and 760 
checked for purity by HPLC as outlined below. Concentration of the solution was adjusted 761 
against chemically synthesized 2'-deoxy-NAD. 762 
HPLC-based Enzyme Assays for NMNAT-2 and CD38 763 
Recombinant human NMNAT-2 (R&D Systems) at a concentration of 5 ng/µL was incubated 764 
for 15 min at 37°C with 290µmol/L β-NMN and 2.5 mmol/L 2ʹ-deoxy-ATP in assay buffer 765 
(50 mmol/L Tris, 10 mmol/L MgCl2, pH 7.6). Afterwards the enzyme was removed by 766 
passing the samples through centrifugal filter devices with 10 kDa cutoff. Reaction products 767 
were analyzed via reversed-phase ion pair (RP)-HPLC on a Multohyp BDS-C18 5µ column 768 
(250 mm x 4.6 mm, particle size 5 μm, CS Chromatographie Service) equipped with a 769 
security guard cartridge (4 mm x 3.0 mm) containing a C18 ODS filter element (Phenomenex) 770 
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at a flow rate of 0.8 mL/min with the buffer (20 mmol/L KH2PO4, 5 mmol/L 771 
tetrabutylammonium dihydrogen phosphate, pH 6) containing increasing amounts of 772 
methanol. The methanol gradient was: 0 min (15%), 3.5 min (15%), 11 min (31.25%), 15 min 773 
(31.25%), 25 min (50%), 27 min (50%), 29 min (15%) and 38 min (15%). The DAD (Diode-774 
Array detector, Agilent Technologies) was set to 260 nm for detection of nucleotides. Peak 775 
integration was performed using ChemStation Software (Rev. C.01.05, Agilent 776 
Technologies). 777 
Peaks co-eluting with chemically synthesized 2ʹ-deoxy-NAD were collected and methanol 778 
was removed on a SpeedVac evaporator. Afterwards pH was adjusted to 7.2 and the MgCl2 779 
concentration to 1 mmol/L. Part of the sample was incubated for 1 h at 37°C with 780 
0.33 Units/mL nucleotide pyrophosphatase from Crotalus adamanteus. The remainder of the 781 
sample was incubated with a recombinant soluble form of human CD38 for 15 min at 37°C. 782 
The putative 2ʹ-deoxy-ADPR peak from the CD38 reaction was collected for pyrophosphatase 783 
digest. In all cases the products were analyzed via reversed-phase ion pair HPLC as described 784 
above. 785 
Substrate saturation plots 786 
To create substrate saturation plots of human NMNAT-2 for the substrates ATP and 2'-deoxy-787 
ATP, 30 ng recombinant NMNAT-2 (R&D Systems) was incubated in 100 µl reaction buffer 788 
(25 mmol/L KH2PO4, 5 mmol/L DTT, 20 mmol/L MgCl2, 0.5 mg/ml bovine serum albumin 789 
(BSA), adjusted to pH 7.5 with KOH) with different concentrations of the substrates (ATP, 2ʹ-790 
deoxy-ATP). For soluble recombinant human CD38, 0.5 ng or 1.0 ng of the enzyme 791 
(produced as described above) was incubated in 100 µl reaction buffer (110 mmol/L KCl, 792 
5 mmol/L KH2PO4, 10 mmol/L NaCl, 2 mmol/L MgCl2, 20 mmol/L HEPES, pH 7.2 mit 793 
KOH) with different concentrations of either NAD or 2'-deoxy-NAD as substrate for 20 min 794 
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at 37°C. Reactions were stopped by cooling the samples rapidly to nearly 0°C and removing 795 
the enzyme by centrifugation through a 10 kDa filter device (VivaSpin, Sartorius) at 4°C. The 796 
amount of product formed was determined by HPLC analysis as described above using 797 
external standards for quantification. In case of CD38 substrate solutions contained minor 798 
contaminations of either ADPR / 2'-deoxy-ADPR that were substracted before kinetic 799 
parameters for the enzyme/substrate pairs were calculated using GraphPad Prism (v6.03, 800 
GraphPad Software). 801 
Immunoprecipitation and western blot analysis of poly-ADP-ribosylated proteins 802 
HEK-293 cells were seeded to 150 mm dishes. Four days later at 80-90% confluence medium 803 
was replaced by pre-warmed buffer (15 mmol/L HEPES, 140 mmol/L NaCl, 5 mmol/L KCl, 804 
1 mmol/L MgCl2, 10 mmol/L Glucose, 1.8 mmol/L CaCl2, pH 7.4) and hydrogen peroxide 805 
was added to a final concentration of 1 mmol/L. After 5 min buffer was replaced by pre-806 
warmed phosphate buffered saline (137.93 mmol/L NaCl, 2.67 mmol/L KCl, 8.06 mmol/L 807 
Na2HPO4, 1.47 mmol/L KH2PO4, 0.493 mmol/L MgCl2, 0.901 mmol/L CaCl2, pH 7.38) and 808 
cells were washed twice. Lysis of cells and isolation of poly ADP-ribosylated proteins was 809 
based on Gagné et al48. Dishes were put on ice and 2 mL lysis buffer (40 mmol/L HEPES, 810 
120 mmol/L NaCl, 1 mmol/L EDTA, 0.3% CHAPS (w/v), pH 7.5) with protease inhibitor 811 
(Roche complete, EDTA-free) and PARG inhibitor ADP-HPD (Enzo Life Sciences) was 812 
added to the cells which then were detached from the dishes and kept on ice for 15 min and on 813 
overhead rotation at 4°C for an additional 20 min. Non-lysed cells were removed by 814 
centrifugation. Paramagnetic beads were washed twice with sodium acetate buffer (0.1 mol/L 815 
Na acetate, pH 5.0) and incubated 30 min at 4°C with either anti-pADPR antibody (10H, 816 
Abcam # ab14459) or mouse normal IgG (Thermo Fisher Scientific) in PBS-T (PBS, 0.02% 817 
Tween20 (v/v)) on overhead rotation. Non-specific binding was prevented by incubation with 818 
blocking buffer for 1 h at room temperature. Directly before addition to the lysed cells beads 819 
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were washed with lysis buffer with protease inhibitor. Beads were incubated with the cell 820 
lysate for 2 h at 4°C on overhead rotation and washed five times with lysis buffer. For 821 
Western blot analysis poly-ADP-ribosylated proteins were eluted from the beads by 822 
incubation in sample buffer (0.22 mol/L Tris, 22.6% (v/v) glycerol, 4% (w/v) SDS, 5.3% 823 
(v/v) 2-mercapto ethanol, pH6.8) at 65°C for 5 min. Afterwards proteins were separated by 824 
10% SDS-PAGE and transferred to a PVDF membrane (Merck, Darmstadt) by tank blotting. 825 
The membrane was blocked in TBS-MT (50 mmol/L Tris, 150 mmol/L NaCl, pH 7.6, 0.1% 826 
Tween20 (v/v), 5% dry milk protein(w/v)) and incubated overnight at 4°C with the primary 827 
anti-PAR antibody (pADPR antibody from rabbit, R&D Systems/Bio-Techne #4336-APC-828 
050) diluted 1:1000 in TBS-MT. The secondary goat anti-rabbit antibody conjugated to 829 
horseradish peroxidase (HRP) (Dianova #111-035-045) was applied in 1:10 000 dilution in 830 
TBS-MT. HRP was detected by chemoluminescence using an Image Quant 831 
LAS4000/LAS3000 (GE Healthcare Life Sciences) after incubation of the membrane in 832 
SuperSignal Working Solution (Thermo Fisher Scientific) for 5 min. 833 
PARG hydrolysis of poly-ADP-ribosylated proteins and HPLC analysis of products 834 
Beads with poly-ADP ribosylated proteins were washed in phosphate buffer (20 mmol/L 835 
KH2PO4, pH 7.2), resuspended in 100 µl phosphate buffer + 10 mmol/L MgCl2 and after 836 
addition of 100 ng recombinant human PARG (Adipogen International) incubated for 2.5 h at 837 
37°C. After removal of beads and PARG by passing the samples through centrifugal filter 838 
devices with 10kD cutoff, 1 µL citric acid, 1 µL chloroacetaldehyde and 33 µL water were 839 
added to 85 µL of the sample and incubated for 40 min at 80°C resulting in conversion of the 840 
adenine nucleotides to the respective fluorescent 1, N6-etheno compounds. Analysis of the 841 
converted nucleotides was based on the method described by Bobalova et al.49 HPLC analysis 842 
was performed on either a 1200 Series system or a 1260 Infinity system (both Agilent 843 
Technologies) using a 250 mm×4.6 mm Multohyp BDS-C18 5µ column (CS 844 
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Chromatographie Service) equipped with a 4.0mm×3.0mm guard cartridge containing a C18 845 
ODS filter element (Phenomenex) at a flow rate of 0.8 mL/min with the buffer (100 mmol/L 846 
KH2PO4, pH 6) containing increasing amounts of methanol. The gradient was: 0 min (0% 847 
methanol), 22.5 min (35% methanol), 25 min (35% methanol), 29 min (0% methanol) and 848 
38 min (0% methanol). Fluorescence of 1, N6-ethenoadenosine was detected at an emission 849 
wavelength of 410 nm after excitation at 230 nm. Peaks were integrated using ChemStation 850 
Software (Rev. C.01.05) from Agilent Technologies. Quantification was performed using 851 
external standards. 852 
Assay for type III CD38 activity using permeabilized cells 853 
106 wildtype Jurkat cells or CD38-/- Jurkat cells were washed, resuspended in 200 µl reaction 854 
buffer (140 mmol/L NaCl, 5 mmol/L KCl, 1 mmol/L NaH2PO4, 1 mmol/L MgSO4, 1 mmol/L 855 
CaCl2, 5.5 mmol/L Glucose, 20 mmol/L HEPES, pH7.4 with NaOH) and incubated with 1, 856 
N6-etheno-NAD at a final concentration of 50 µmol/L. Reaction was stopped after 0, 5, 10, 15 857 
and 30 min by spinning down the cells and passing the supernatant through a centrifugal filter 858 
device with 10kD cutoff. Samples were analysed by HPLC using fluorescence detection as 859 
described below, to determine the amount of 1, N6-etheno-ADPR formed. Reaction rates were 860 
calculated from the increase in product by linear regression. To block the activity of CD38 on 861 
the cell surface, cells were incubated in 1 µmol/L araF-NAD in reaction buffer for either 862 
40 min or 90 min at RT. Excess araF-NAD was removed by washing the cells in reaction 863 
buffer prior to the determination of the CD38 activity. To selectively permeabilize the plasma 864 
membrane 106 cells were washed once in intracellular buffer (120 mmol/L KCl, 10 mmol/L 865 
NaCl, 1.2 mmol/L MgCl2, 0.533 mmol/L CaCl2, 10 mmol/L HEPES, 1 mmol/L EGTA, pH7.2 866 
with KOH) and resuspended in intracellular buffer with 90 µg/mL saponin. After incubation 867 
at 37°C for 5 min cells were washed in nominally Ca2+ free intracellular buffer (120 mmol/L 868 
KCl, 10 mmol/L NaCl, 1.2 mmol/L MgCl2, 10 mmol/L HEPES, pH7.2 with KOH) twice 869 
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before CD38 activity was determined using 1, N6-etheno-NAD as described above. To test 870 
whether residual activity was due to CD38, permeabilized cells were also incubated with 871 
1 µmol/L araF-NAD for 40 min at RT. Excess araF-NAD was removed by washing the cells 872 
prior to the determination of the CD38 activity as described above. 873 
 874 
Quantification of endogenous 2ʹ-deoxy-ADPR by HPLC 875 
1x108 Jurkat cells at a cell density of 1x106 cells/mL were harvested from suspension, washed 876 
twice in Ca2+ measurement buffer (140 mmol/L, NaCl, 5 mmol/L KCl, 1 mmol/L MgSO4, 877 
1 mmol/L CaCl2, 1 mmol/L NaH2PO4, 5.5 mmol/L D-glucose and 20 mmol/L HEPES, pH 878 
7.4) and resuspended in 5 mL of the same buffer. After 25 min at 25°C hydrogen peroxide 879 
was added to a final concentration of 100 µmol/L. An additional 2 or 5 minutes later cells 880 
were collected by centrifugation and nucleotides extracted from the cells by addition of 881 
trichloroacetic acid, freeze/thawing and sonication. Denatured proteins and nucleic acids were 882 
removed by centrifugation and 25 pmol 1, N6-ethenoadenosine was added to the supernatant 883 
as internal standard. Trichloroacetic acid was removed by four cycles of extraction with 884 
diethyl ether. To remove residual diethyl ether samples were dried using a SpeedVac 885 
evaporator and reconstituted in water. After samples were filtered through 0.2 µm syringe 886 
filter devices, samples were again dried and reconstituted in 15% methanol/water. HPLC 887 
analysis was performed on either a 1200 Series system or a 1260 Infinity system (both Agilent 888 
Technologies). The first step of chromatographic separation was run on a 250 mm×10 mm 889 
Luna C8 5 µm column (Phenomenex) equipped with a 10 mm×10 mm guard cartridge 890 
containing a C8 ODS filter element (Phenomenex) at a flow rate of 2.5 mL/min with the 891 
buffer (20 mmol/L KH2PO4, 5 mmol/L tetrabutylammonium dihydrogen phosphate, pH 6) 892 
containing increasing amounts of methanol. The gradient was: 0  min (15% methanol), 893 
3.5 min (15% methanol), 11 min (31.25% methanol), 15 min (31.25% methanol), 25 min 894 
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(50% methanol), 27 min (50% methanol) , and 29 min (15% methanol). Adenine nucleotides 895 
were detected using the DAD (photo diode array detector) at 260 nm. Fluorescence of 1, N6-896 
ethenoadenosine was detected at an emission wavelength of 410 nm after excitation at 897 
275 nm. Two fractions of roughly 2.5 mL were manually collected around the retention times 898 
of 1, N6-ethenoadenosine (Rt 13.5 min) and 2ʹ-deoxy-ADPR (Rt 24.5 min). Fractions were 899 
dried on a SpeedVac evaporator and reconstituted in 15% methanol/water. After 900 
reconstitution samples were split into twin samples. For the 2ʹ-deoxy-ADPR fractions one of 901 
the samples was spiked with 15.625 pmol 2ʹ-deoxy-ADPR. The second step of 902 
chromatographic analysis was run on a 250 mm×4.6 mm Multohyp BDS-C18 5µ column (CS 903 
Chromatographie Service) equipped with a 4.0 mm×3.0 mm guard cartridge containing a C18 904 
ODS filter element (Phenomenex) at a flow rate of 0.8 mL/min using the same buffer system 905 
and detection as above. The gradient was: 0 min (15% methanol), 3.5 min (15% methanol), 906 
11 min (31.25% methanol), 15 min (31.25% methanol), 25 min (50% methanol), 27 min 907 
(50% methanol) , and 29 min (15% methanol). Peaks were integrated using ChemStation 908 
Software (Rev. C.01.05) from Agilent Technologies. Samples with peaks unsufficiently 909 
resolved for proper integration were excluded. Quantification was performed using external 910 
standards. Recovery was determined from the internal standard 1,N6-ethenoadenosine. Results 911 
for 2ʹ-deoxy-ADPR were corrected for recovery. 912 
 913 
HPLC of endogenous 2ʹ-deoxy-ADPR and 2ʹ-deoxy-NAD for HRMS and quantification of 914 
endogenous 2ʹ-deoxy-NAD, NAD and ADPR 915 
1x108 wild type Jurkat cells or CD38-/- Jurkat cells per sample were prepared as described 916 
above and either left unstimulated or stimulated for 5 min with 100 µmol/L hydrogen 917 
peroxide. After deproteination and extraction of the trichloroacetic acid by diethyl ether, 918 
samples were dried on a SpeedVac evaporator to remove residual diethyl ether and 919 
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reconstituted in water. After samples were filtered through 0.2 µm syringe filter devices, 920 
samples were again dried on a SpeedVac evaporator and reconstituted in 3% methanol/water. 921 
HPLC analysis was performed on either a 1200 Series system or a 1260 Infinity system (both 922 
Agilent Technologies). The first step of chromatographic separation was run on a 923 
250 mm×10 mm Luna C8 5 µm column (Phenomenex) equipped with a 10 mm×10 mm guard 924 
cartridge containing a C8 ODS filter element (Phenomenex) at a column temperature of 20°C 925 
and a flow rate of 2.5 mL/min with the buffer (50 mmol/L ammonium acetate, 0.05% acetic 926 
acid, pH 5.4) containing increasing amounts of methanol. The gradient was: 0 min 927 
(3% methanol), 5 min (3% methanol), 35 min (50% methanol), 38 min (50% methanol), 45 928 
min (3% methanol), and 50 min (3% methanol). Adenine nucleotides were detected as 929 
described above. Five fractions of roughly 2.5 mL were manually collected around the 930 
retention times of ADPR (Rt 8.2 min), NAD (Rt 12.9 min), 2ʹ-deoxy-ADPR (Rt 13.9 min), 2ʹ-931 
deoxy-NAD (Rt 16.5 min), and 1, N6-ethenoadenosine (Rt 24.5 min). All fractions were dried 932 
on a SpeedVac evaporator. The fractions containing ADPR, NAD and 1, N6-ethenoadenosine 933 
were reconstituted in buffer (20 mmol/L KH2PO4, 5 mmol/L tetrabutylammonium dihydrogen 934 
phosphate, pH 6 containing 15% methanol) whereas the fractions containing 2ʹ-deoxy-ADPR 935 
and 2ʹ-deoxy-NAD were reconstituted in 3% methanol/water. After reconstitution all samples 936 
except the ones for 1, N6-ethenoadenosine were split into twin samples. One half of the twin 937 
sample was spiked with an appropriate amount of the respective nucleotide (ADPR with 100 938 
or 250 pmol, NAD with 5 nmol, 2ʹ-deoxy-ADPR with 62.5 pmol and 2ʹ-deoxy-NAD with 939 
15.63 pmol). The samples with ADPR, NAD, and 1, N6-ethenoadenosine were run on a 940 
Multohyp BDS-C18 5µ column using the same (ion pair) conditions as described above. For 941 
the samples with 2ʹ-deoxy-ADPR and 2ʹ-deoxy-NAD which were to be submitted to HRMS 942 
the second step of chromatographic analysis was run on a 250 mm×4.6 mm Multohyp BDS-943 
C18 5µ column (CS Chromatographie Service) equipped with a 4.0 mm×3.0 mm guard 944 
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cartridge containing a C18 ODS filter element (Phenomenex) at a column temperature of 945 
25°C and a flow rate of 0.8 mL/min with the buffer (50 mmol/L ammonium acetate, 0.05% 946 
acetic acid, pH 5.4) containing increasing amounts of methanol. The gradient was: 0 min 947 
(3% methanol), 7 min (3% methanol), 32 min (50% methanol), 35 min (50% methanol), 41 948 
min (3% methanol), and 45 min (3% methanol). Adenine nucleotides were detected as 949 
described above. Separate fractions of roughly 500 µL were manually collected for 2ʹ-deoxy-950 
ADPR (Rt 10.85 min) and 2ʹ-deoxy-NAD (Rt 17.2 min) around the retention times of the 951 
respective standards. Fractions were dried on a SpeedVac evaporator and submitted to 952 
HRMS. Quantification using external standards was done as described above. Recovery was 953 
determined from the internal standard 1, N6-ethenoadenosine. Since recovery was always 954 
around 100% results were not corrected during these experiments. 955 
High resolution mass spectrometry(HRMS) 956 
HRMS was carried out using ultrahigh resolution ESI-QTOF on a maXis HD Bruker 957 
Daltonics instrument in negative mode with direct injection (50 µL). Spectra were acquired in 958 
full scan mode in the mass range 100 – 750 m/z and the baseline subtracted (MilliQ water). 959 
Generation of CD38-/- Jurkat cell line using CRISPR/Cas9 960 
Knock-out of CD38 in Jurkat subclone JMP was performed by CRISPR/Cas9 using the 961 
expression plasmids pX330-Puro-T2A-hCas9 and pCAG-EGxxFP, which were kindly 962 
provided by Prof. Dr. Alexander Flügel (Department of Neuroimmunology, University 963 
Medical Center Göttingen, Göttingen, Germany). The sgRNA sequence 964 
(CCACCGCGAGCACCACGACG) was designed with the GenScript gRNA design tool 965 
(http://www.genscript.com/gRNA-design-tool.html). The adapted expression plasmids were 966 
co-transfected into Jurkat cells by electroporation. EGFP positive cells from the transfection 967 
were sorted and individualized by FACS (FACS Sorting Core Unit, University Medical 968 
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Centre Hamburg-Eppendorf, Germany). Resulting Jurkat clones were characterized regarding 969 
CD38 protein expression and NAD glycohydrolase activity. 970 
Preparation of membrane fractions from Jurkat cells 971 
Membrane fractions from Jurkat cells were prepared as described previously50,51. Briefly, 972 
either 5x107 wild type Jurkat cells or CD38-/- Jurkat cells were suspended in lysis buffer 973 
(110 mmol/L NaCl, 20 mmol/L HEPES, pH 7.4) with protease inhibitor mix (Roche) and 974 
disrupted using a dounce homogenizer. After removal of undisrupted cells and intact nuclei, 975 
membranes were enriched by centrifugation at 10 000xg. The membrane pellet was 976 
resuspended in lysis buffer and protein content determined by Bradford protein assay (Bio-977 
Rad) against BSA as standard. 978 
Assay of NAD glycohydrolase activity 979 
NAD glycohydrolase activity in P10 membranes from wild type Jurkat cells or CD38-/- Jurkat 980 
cells was determined as described previously50,51. Briefly, 20 µg of P10 membrane proteins 981 
from wild type Jurkat cells or CD38-/- Jurkat cells were incubated with 1, N6-etheno-NAD 982 
(100 µmol/L) in buffer (140 mmol/L, NaCl, 5 mmol/L KCl, 1 mmol/L MgSO4, 1 mmol/L 983 
CaCl2, 1 mmol/L NaH2PO4, 5.5 mmol/L D-glucose and 20 mmol/L HEPES, pH 7.4). In the 984 
course of the reaction fluorescence is increasing due to the higher fluorescence of the product 985 
1, N6-etheno-ADPR compared to the substrate. The increase in fluorescence was followed 986 
(excitation at 300 nm, emission at 410 nm) using an Infinite M200 micro plate reader (Tecan). 987 
The amount of product formed was calculated from the fluorescence readings using a 1, N6-988 
etheno-ADPR standard curve. 989 
Western Blot analysis of CD38 activity 990 
CD38 expression in Jurkat cells was analyzed as described recently50,51. Briefly 60 µg of P10 991 
membrane proteins from wild type and CD38-/- Jurkat cells were separated on a 12% non-992 
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reducing SDS-PAGE (0.4% SDS) and subsequently transferred to a PVDF membrane 993 
(Immobilon-FL, Millipore). The membrane was probed with a primary antibody against 994 
human CD38 (1:200, mouse monoclonal antibody AT-1, Santa Cruz Biotechnology #sc-7325) 995 
and a secondary goat anti-mouse antibody conjugated to horse radish peroxidase (1:10 000, 996 
Santa Cruz Biotechnology #sc-2302). Incubation of the membrane in SuperSignal Working 997 
Solution (Thermo Fisher Scientific) for 5 min allowed for detection of the secondary antibody 998 
by chemiluminescence using an Image Quant LAS4000/LAS3000 (GE Healthcare Life 999 
Sciences). 1000 
Statistical Analysis 1001 
Statistical analysis was performed using GraphPad Prism (v 6.03, GraphPad Software). 1002 
Quantitative data were tested for normality using D’Agostino-Pearson Omnibus Test 1003 
(α=0.05). If all groups were normally distributed, data is reported as mean±SEM (standard 1004 
error of the mean) and parametric tests were used (unpaired, two-tailed T-test or one-way 1005 
ANOVA). In case of non-normal distribution or if the sample size for groups was too small to 1006 
test for normality, data is reported as median with interquartile range and non-parametric tests 1007 
(Mann-Whitney test, Kruskal-Wallis test) were chosen. If non-normal data were to be 1008 
compared against a hypothetical value (especially against 0) a Wilcoxon Signed Rank Test 1009 
was used. Post-hoc tests were performed as Holm-Sidak or Dunn’s test with p-values 1010 
corrected for multiple testing. 1011 
Linear and non-linear regression analysis was performed using GraphPad Prism (v 6.03, 1012 
GraphPad Software). For fitting of concentration-response curves (Fig. 2) a four parameter 1013 
logistic model has been chosen. Conditions were: bottom value constrained to 0 and Hill 1014 
coefficient shared between data sets. For the analysis of channel inactivation (Fig. 3e+f) a 1015 
histogram of the frequency distribution with a bin width of 5 s was generated and a one phase 1016 
exponential decay function fitted to the data by non-linear regression. To test whether 1017 
 43 
 
 
parameters of fit differ between conditions extra-sum-of-squares F tests were used. In case of 1018 
the slope conductance (Fig. 3c) data were fitted to a linear equation (without intercept). To 1019 
compare the slope conductance between channel variants and agonists the results from the 1020 
linear regression (slope±SEM) were tested by multiple unpaired, two-tailed T-tests assuming 1021 
normal distribution of the residuals and without correction for multiple testing. 1022 
An a priori power analysis to determine sample sizes has not been done. For all statistical tests 1023 
a significance level α of 0.05 was adopted.  1024 
  1025 
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